Estrogen and cardiovascular disease: Is timing everything?

American Journal of the Medical Sciences

Volumn 350, Issue 1, 2015, Pages 27-35

  Giordano, Samantha ^a,b,c   Hage, Fadi G ^a,b,c   Xing, Dongqi ^a,b,c   Chen, Yiu Fai ^a,b,c   Allon, Steven ^a,b,c   Chen, Chongjia ^a,b,c   Oparil, Suzanne ^a,b,c  

^a Division of Cardiovascular Disease   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Estrogen; Menopause; Timing hypothesis

Indexed keywords

ESTRADIOL; ESTROGEN; PROGESTERONE; TUMOR NECROSIS FACTOR ALPHA;

AGE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); ESTROGEN THERAPY; FEMALE; FIBROBLAST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; MACROPHAGE; MENOPAUSE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLATIONAL RESEARCH; UTERINE ARTERY; VASCULAR SMOOTH MUSCLE CELL; WOMEN'S HEALTH; ADULT; AGED; AGING; CARDIOVASCULAR DISEASES; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; AGE FACTORS; AGED; AGING; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED;

EID: 84936871939     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000512     Document Type: Conference Paper

References (58)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. AHA statistical update heart disease and stroke statistics-2015 update. Circulation 2015;131: e29-e322.
2. Van der Schow YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347:714-18.
3. Bowling M, Oparil S, Hage F, et al. Chapter 1: sex hormones and vascular function. Sex Horm 2012:1-31.
4. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
5. Magliano DJ, Rogers SL, Abramson MJ, et al. Hormone therapy and cardiovascular disease: a systemic review and meta-analysis. BJOG 2006;113:5-14.
6. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and unified hypothesis. Fertil Steril 2005;83:558-66.
7. Barrett-Conner E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19: 55-72.
8. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA 1998;280:605-13.
10. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
11. Writing Group for the Women's Health Initiative. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701-12.
12. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409.
13. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249-60.
14. Hodis HN, Mack WJ, Shoupe D, et al. Abstract 13283: testing the menopausal hormone therapy timing hypothesis: early versus late intervention trial with estradiol. Circulation 2014;130:A13283.
15. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JAAC Cardiovasc Interv 2008;1:211-17.
16. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-6.
17. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;3:199-210.
18. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than non-users? Am J Epidemiol 1996;143:971-8.
19. Grady D, Herrington DM, Bittner V, et al; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone replacement: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
20. Herrington DM. The HERS trial results: paradigms lost? Ann Intern Med 1999;131:463-6.
21. Alving B. NIH news, NIH asks participants in women's health initiative estrogen-alone study to stop study pills, begin follow up phase. 2004. Available at: http://www.nhlbi.nih.gov/whi/pr-04-3-2.pdf. Accessed March 22, 2015.
22. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogen among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14.
23. Hersh AL, Stefanick ML, Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
24. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention of in women. J Am Coll Cardiol 2004;43:900-21.
25. Dubey RK, Imthurn B, Zacharia LC, et al. Hormone replacement therapy and cardiovascular disease. What went wrong and where do we go from here? Hypertension 2004;44:789-95.
26. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-26.
27. Toh S, Hernández-Díaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010;152:211-17.
28. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011;124:199-205.
29. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the women's health initiative randomized trials. JAMA 2013;310:1353-68.
30. Shufelt CL, Merz NB, Prentice RL, et al. Hormone therapy, dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the women's health initiative observational study. Menopause 2014;21;260-6.
31. Sarrel PM, Nijike VY, Vinante V, et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50-59. Am J Public Health 2013;103:1583-8.
32. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Prevention Study (KEEPS). J Cardiovasc Transl Res 2009;2:228-39.
33. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the kronos early estrogen prevention study. Climacteric 2005;8:2-12.
34. Miller VM, Petterson TM, Jeavons EN, et al. Genetic polymorphisms associated with carotid intima-media thickens and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics 2013;45:79-88.
35. Quinones MP, Martinez HG, Jimenez F, et al. CC chemokine receptor 5 influences late stage atherosclerosis. Atherosclerosis 2007;195:e92-e103.
36. Braunersreuther V, Zernecke A, Araud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007;27:373-9.
37. Heit JA, Armasu SM, Asmann YW, et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012;10:1521-31.
38. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular Protection. Arterioscler Thromb Vasc Biol 2009;29:289-95.
39. Chen SJ, Li H, Durand J, et al. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-84.
40. Levine R, Chen SJ, Durand J, et al. Medroxyprogesterone attenuated estrogen-mediated inhibition of neointima formation after balloon injury of the carotid artery. Circulation 1996;94:2221-7.
41. Sunday L, Tran MM, Krause DN, et al. Estrogen and progestogens differentially modulate vascular pro-inflammatory factors. Am J Physiol 2006;291:E261-7.
42. Mori T, Durand J, Chen YF, et al. Effects of short-term estrogen treatment on the neointimal response to the balloon injury of rat carotid artery. Am J Cardiol 2000;85:1276-9.
43. Xing D, Miller A, Novak L, et al. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 2004;109:234-41.
44. Miller AP, Feng W, Xing D, et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004;110:1664-69.
45. Xing D, Feng W, Miller AP, et al. Estrogen modulates TNF-induced inflammation in rat aortic smooth muscle cells through estrogen receptor activation. Am J Physiol 2007;292:H2607-12.
46. Xing D, Oparil S, Yu H, et al. Estrogen modulates NFkB signaling by enhancing Ikba levels and blocking p65 binding at the promotors of inflammatory genes via estrogen receptor-b. PLoS One 2012;7:e36890.
47. Oparil S, Chen SJ, Chen YF, et al. Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Car-diovasc Res 1999;44:608-14.
48. Li G, Chen YF, Greene GL, et al. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 1999;100:1639-45.
49. 3-depen-dent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation 2000;101:2949-55.
50. Miller AP, Xing D, Feng W, et al. Aged rats lose vasoprotective and anti-inflammatory effects of estrogen in injured arteries. Menopause 2007;14:251-60.
51. Xing D, Hage FG, Chen YF, et al. Exaggerated neointima formation in human C-reactive protein transgenic mics is IgG Fc receptor type 1 (Fc gamma RI)-dependent. Am J Pathol 2008;172:22-30.
52. Wang D, Oparil S, Chen YF, et al. Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005;25:2094-9.
53. Hage FG, Oparil S, Xing D, et al. C-reactive protein-mediated vascular injury requires complement. Arterioscler Thromb Vasc Biol 2010; 30:1189-95.
54. Bowling MR, Xing D, Kapadia A, et al. Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors. Arterioscler Thromb Vasc Biol 2014;34:1477-85.
55. Chakrabarti S, Davidge ST. G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. PLoS One 2012;12:e52357.
56. Meyer MR, Fredette NC, Howard TA, et al. G-Protein coupled estrogen receptor protects from atherosclerosis. Sci Rep 2014;4:7564.
57. Hage FG, Xing D, Guo Y, et al. Estrogen-induced vasoprotection is preserved after prolonged estrogen deprivation. Circulation 2014;130:A14875.
58. Novella S, Heras M, Hermenegildo C, et al. Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 2012;32:2035-42.